← Back to Screener
Viking Therapeutics, Inc (VKTX)
Price$28.45
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-30.64%
Price vs S&P 500 (4W)-9.18%
VGM Score41.56
Market Capitalization$3.41B
All Metrics
Book Value / Share (Quarterly)$4.33
P/TBV (Annual)8.45x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.94
Price vs S&P 500 (YTD)-27.29%
EPS (TTM)$-4.15
10-Day Avg Trading Volume1.88M
EPS Excl Extra (TTM)$-4.15
EPS (Annual)$-3.19
ROI (Annual)-56.28%
Cash / Share (Quarterly)$5.20
ROA (Last FY)-50.25%
EBITD / Share (TTM)$-4.42
ROE (5Y Avg)-33.61%
Cash Flow / Share (Annual)$-2.43
P/B Ratio6.78x
P/B Ratio (Quarterly)7.51x
Net Income / Employee (Annual)$-6,095,600
Net Interest Coverage (TTM)-10.12x
ROA (TTM)-65.35%
EPS Incl Extra (Annual)$-3.19
Current Ratio (Annual)9.33x
Quick Ratio (Quarterly)5.67x
3-Month Avg Trading Volume2.48M
52-Week Price Return5.21%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.68
52-Week High$43.15
EPS Excl Extra (Annual)$-3.19
Tangible BV CAGR (5Y)60.93%
26-Week Price Return-22.71%
Quick Ratio (Annual)9.21x
13-Week Price Return-9.71%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.72x
Enterprise Value$3.29B
Book Value / Share Growth (5Y)10.78%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.15
3-Month Return Std Dev51.20%
Net Income / Employee (TTM)$-8,005,700
ROE (Last FY)-56.28%
Net Interest Coverage (Annual)-12.22x
EPS Basic Excl Extra (Annual)$-3.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.15
ROI (TTM)-71.31%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.86
Price vs S&P 500 (52W)-19.15%
Year-to-Date Return-19.13%
5-Day Price Return-9.02%
EPS Normalized (Annual)$-3.19
ROA (5Y Avg)-30.53%
Month-to-Date Return-13.10%
EBITD / Share (Annual)$-3.49
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-33.61%
LT Debt / Equity (Quarterly)0.49x
EPS Basic Excl Extra (TTM)$-4.15
P/TBV (Quarterly)3.34x
P/B Ratio (Annual)6.22x
Book Value / Share (Annual)$5.57
Price vs S&P 500 (13W)-17.97%
Beta0.71x
Revenue / Share (TTM)$0.00
ROE (TTM)-71.31%
52-Week Low$22.96
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-1.37est. -1.03
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.29
4.29
4.24
4.24
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VKTXViking Therapeutics, Inc | — | — | C | $28.45 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Viking Therapeutics is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its clinical pipeline includes VK2809 and VK0214, oral selective thyroid hormone receptor beta agonists, and VK5211, an oral selective androgen receptor modulator, each targeting unmet medical needs in hormonal conditions.